Study on the Role of Zoledronic Acid in Treatment of Postmenopausal Osteoporosis Women

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2014 Feb 20

PMID 24550958

Citations 7

Authors

Ma Chao

Qin Hua

Zhou Yingfeng

Wan Guang

Shi Shufeng

Dong Yuzhen

Wang Wei

Tan Haifeng

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to assess the role of zoledronic acid (ZOL) on the risk of fracture and bone mineral density (BMD) in women with osteoporosis.

Methods: A double-blind and placebo-controlled design was taken in our study. 327 patients who received an intravenous 5-mg infusion zoledronic acid at day 0, at 12 months were enrolled in treatment group, and the remaining 333 patients who received placebo at the same time of the treatment group were included as control group. The incidence of fracture and BMD in the femoral neck and total hip were assessed.

Results: ZOL group had lower incidence of fracture at any clinical fracture, clinical vertebral fracture, non-vertebral fracture and hip fracture compared with placebo group at the time of one year and three years. We found that the BMD were significantly increased at femoral neck and total hip in ZOL group at the time of one year and three years follow-up when compared with placebo group (P<0.05). The adverse events in the ZOL within three days of drug infusion were significantly higher than the control group, but we did not find significant difference in the serious adverse effect between the two groups.

Conclusions: Zoledronic acid (ZOL) could be used as a safe and effective method for female with osteoporosis.

Citing Articles

Effect of Zoledronic Acid in Hepatic Osteodystrophy: A Double-Blinded Placebo-Controlled Trial.

Raj H, Kamalanathan S, Sahoo J, Mohan P, Nagarajan K, Reddy S Indian J Endocrinol Metab. 2024; 27(6):552-558.

PMID: 38371182 PMC: 10871003. DOI: 10.4103/ijem.ijem_233_23.

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis.

Gazoni F, Civile V, Atallah A, Santos F, Trevisani V Sao Paulo Med J. 2023; 141(6):e2022480.

PMID: 37255065 PMC: 10214983. DOI: 10.1590/1516-3180.2022.0480.R1.27032023.

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.

Zhou W, Liu Y, Guo X, Yang H, Xu Y, Geng D Osteoporos Int. 2019; 30(8):1581-1589.

PMID: 31115592 DOI: 10.1007/s00198-019-05005-7.

Use of amniotic membrane in the treatment of patients with BRONJ: two case reports.

Ragazzo M, Trojan D, Spagnol L, Paolin A, Guarda Nardini L J Surg Case Rep. 2018; 2018(4):rjy073.

PMID: 29692884 PMC: 5909437. DOI: 10.1093/jscr/rjy073.

Clinical Management of Osteoporotic Fractures.

Khan A, Rames R, Miller A Curr Osteoporos Rep. 2018; 16(3):299-311.

PMID: 29637519 DOI: 10.1007/s11914-018-0443-y.

References

Hwang J, Chen J, Yang T, Wu D, Tsai K, Ho C . The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Calcif Tissue Int. 2008; 83(5):308-14. DOI: 10.1007/s00223-008-9180-z. View

Black D, Reid I, Boonen S, Bucci-Rechtweg C, Cauley J, Cosman F . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27(2):243-54. PMC: 3427916. DOI: 10.1002/jbmr.1494. View

Popp A, Guler S, Lamy O, Senn C, Buffat H, Perrelet R . Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res. 2012; 28(3):449-54. DOI: 10.1002/jbmr.1775. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Yen M, Yen B, Jang M, Hsu S, Cheng W, Tsai K . Effects of alendronate on osteopenic postmenopausal Chinese women. Bone. 2000; 27(5):681-5. DOI: 10.1016/s8756-3282(00)00384-7. View

Hashimoto M, Hotokezaka H, Sirisoontorn I, Nakano T, Arita K, Tanaka M . The effect of bone morphometric changes on orthodontic tooth movement in an osteoporotic animal model. Angle Orthod. 2013; 83(5):766-73. PMC: 8744520. DOI: 10.2319/111312-869.1. View

Boonen S, Black D, Colon-Emeric C, Eastell R, Magaziner J, Eriksen E . Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010; 58(2):292-9. PMC: 3660706. DOI: 10.1111/j.1532-5415.2009.02673.x. View

Jacques R, Boonen S, Cosman F, Reid I, Bauer D, Black D . Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 27(8):1627-34. DOI: 10.1002/jbmr.1644. View

Xu L, Deng H, Zhi X, Zhang W, Wang X, Wu W . [Therapeutic effect of zoledronic acid on primary osteoporosis in elderly patients]. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32(9):1287-9. View

10.

Nshimyumukiza L, Durand A, Gagnon M, Douville X, Morin S, Lindsay C . An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res. 2012; 28(2):383-94. PMC: 3580046. DOI: 10.1002/jbmr.1758. View

11.

Reginster J, Minne H, Sorensen O, Hooper M, Roux C, Brandi M . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11(1):83-91. DOI: 10.1007/s001980050010. View

12.

Eastell R, Black D, Boonen S, Adami S, Felsenberg D, Lippuner K . Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009; 94(9):3215-25. PMC: 5101059. DOI: 10.1210/jc.2008-2765. View

13.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

14.

Genant H, Wu C, van Kuijk C, Nevitt M . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9):1137-48. DOI: 10.1002/jbmr.5650080915. View

15.

Viswanathan H, Curtis J, Yu J, White J, Stolshek B, Merinar C . Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy. Appl Health Econ Health Policy. 2012; 10(3):163-73. DOI: 10.2165/11598590-000000000-00000. View

16.

Hwang J, Tu S, Yang T, Chen J, Wang C, Tsai K . Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int. 2006; 17(3):373-8. DOI: 10.1007/s00198-005-2002-5. View

17.

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View